GleamWall
中文EN

HURA TuHURA Biosciences, Inc./NV

Pharmaceutical Preparations · Nasdaq · SEC CIK 1498382 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-2.2%
TTM EPS YoY-47.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-167.5%
ROA-96.6%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets47.7%
Debt / equity0.49x
Current ratio0.47x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.79x
Accruals ratio-20.4%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$0$0
R&D expense$20.53M$13.34M
SG&A expense$7.58M$3.87M
Interest expense$625,283$4.14M
Pretax income-$30.05M-$21.68M
Income tax$1,600$3,768
Net income-$30.05M-$21.68M
EPS (basic)-0.63-1.21
EPS (diluted)-0.63-1.21
Weighted avg. shares (diluted)47.93M18.66M
Balance sheet
Cash & equivalents$3.62M$12.66M
Current assets$4.62M$19.61M
PP&E, net$300,639$123,366
Goodwill$10.74M—
Total assets$27.35M$19.97M
Current liabilities$5.92M$5.33M
Total liabilities$6.42M$5.37M
Shareholders' equity$20.93M$14.59M
Shares outstanding59.34M12.17M
Cash flow statement
Operating cash flow-$27.63M-$14.73M
Capital expenditure$76,083$57,906
Free cash flow-$27.71M-$14.79M
Investing cash flow-$1.34M-$6.05M
Financing cash flow$19.93M$29.77M
Depreciation & amortization$71,265$116,710
Stock-based compensation$6.42M$1.96M

Free plan shows the latest 2 periods; Pro shows all 19 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.